Cargando…

Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

Testing for the BRAF mutation is mandatory for the management of patients with locally advanced or metastatic melanoma. Molecular analysis based on DNA sequencing remains the gold-standard method for the screening of the different BRAF mutations. These methods must be rapid, sensitive, and specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long-Mira, Elodie, Picard-Gauci, Alexandra, Lassalle, Sandra, Hofman, Véronique, Lalvée, Salomé, Tanga, Virginie, Zahaf, Katia, Bonnetaud, Christelle, Lespinet, Virginie, Camuzard, Olivier, Montaudié, Henri, Poissonnet, Gilles, Passeron, Thierry, Ilié, Marius, Hofman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947166/ https://www.ncbi.nlm.nih.gov/pubmed/35328303 http://dx.doi.org/10.3390/diagnostics12030751

Ejemplares similares

Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
por: Lassalle, Sandra, et al.
Publicado: (2020)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution
por: Heeke, Simon, et al.
Publicado: (2020)

Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank
por: Martel, Arnaud, et al.
Publicado: (2023)

In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients
por: Heeke, Simon, et al.
Publicado: (2019)

Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France)
por: Ilié, Marius, et al.
Publicado: (2022)

Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice
por: Martel, Arnaud, et al.
Publicado: (2023)

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients
por: Heeke, Simon, et al.
Publicado: (2018)

High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness
por: Long, Elodie, et al.
Publicado: (2016)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
por: Heeke, Simon, et al.
Publicado: (2021)

Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma
por: Ilié, Marius, et al.
Publicado: (2021)

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
por: Hofman, Véronique, et al.
Publicado: (2018)

New Targeted Therapies and Immunotherapies for Locally Advanced Periocular Malignant Tumours: Towards a New ‘Eye-Sparing’ Paradigm?
por: Martel, Arnaud, et al.
Publicado: (2021)

Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer
por: Ilie, Marius, et al.
Publicado: (2017)

Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test
por: Hofman, Paul, et al.
Publicado: (2021)

Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load Specimens
por: Ilié, Marius, et al.
Publicado: (2023)

Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?
por: Washetine, Kevin, et al.
Publicado: (2018)

The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d’Azur, Nice, France)
por: Bontoux, Christophe, et al.
Publicado: (2023)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA
por: Washetine, Kevin, et al.
Publicado: (2018)

A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer
por: Hofman, Véronique, et al.
Publicado: (2023)

Identification of a circulating immunological signature predictive of response to immune checkpoint inhibitors in patients with advanced non‐small cell lung cancer
por: Khatir, Wassila, et al.
Publicado: (2022)

“Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease
por: Ilie, Marius, et al.
Publicado: (2014)

Salivary detection of COVID-19: clinical performance of oral sponge sampling for SARS-CoV-2 testing
por: Boutros, Jacques, et al.
Publicado: (2021)

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients
por: Ilie, Marius, et al.
Publicado: (2017)

Setting-Up a Rapid SARS-CoV-2 Genome Assessment by Next-Generation Sequencing in an Academic Hospital Center (LPCE, Louis Pasteur Hospital, Nice, France)
por: Hofman, Paul, et al.
Publicado: (2022)

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?
por: Hofman, Paul, et al.
Publicado: (2019)

A rapid near-patient RT-PCR test for suspected COVID-19: a study of the diagnostic accuracy
por: Hofman, Paul, et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma
por: Bozec, Alexandre, et al.
Publicado: (2017)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study
por: Fontas, E., et al.
Publicado: (2021)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
por: Valet, Orion, et al.
Publicado: (2021)

BRAF(V600E) Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
por: Gourdin, Guillaume, et al.
Publicado: (2023)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t5f4hhrtn3ipjgposfjbtgfi34